An Open-label, Single Dose Pharmacokinetic Study of 14 mg Granisetron Patch in Healthy Subjects (Granisetron)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00954291
Verified September 2010 by Taipei Medical University WanFang Hospital. Recruitment status was: Recruiting
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
20 Years to 40 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Subjects must be male at the age of 20-40 years old in good health on the basis of medical history, physical examination, electrocardiogram, chest X-ray, and routine laboratory evaluations.
Vital signs (after 3 minutes resting in a upright position) which are within the following ranges: Ear body temperature between 35.0-37.5 °C.Systolic blood pressure, 90-140 mm Hg.Diastolic blood pressure, 50-90 mm Hg.Pulse rate, 50-90 bpm.Fasting blood glucose, < 100 mg/dL.
Body weight must be above 50 kg and within -20 to +20% of ideal body weight.
Able to sign informed consent prior to study.
Able to communicate well with the investigator and comply with the requirements of the study.
Use of any prescription medication within 14 days prior to dosing.
Use of over-the-counter medications or vitamins within 14 days prior to dosing.
Significant illness within 2 weeks prior to dosing.
Participation in any clinical investigation within 2 months prior to dosing or longer than required by local regulation.
Donate or loss more than 500 mL of blood within 3 months prior to dosing.
Presence of cardiovascular disease.
Presence of gastrointestinal disease.
Presence of asthma or lung disease.
Presence of liver disease, hepatitis B, hepatitis C or liver injury as indicated by an abnormal liver function profile such as GOT, GPT, g-GT, alkaline phosphatase, serum bilirubin, HBsAg, or Anti-HCV.
Presence of impaired renal function as indicated by abnormal creatinine or BUN values or abnormal urinary constituents (e.g., albuminuria).
Presence of neurological disease.
Presence of psychiatrical disease.
Subject is known for HIV infected.
A known hypersensitivity to granisetron or its analogs.
History of drug or alcohol abuse within 12 months prior to dosing.
Permanent confinement to an institution.
Individuals are judged by the investigator or pharmacokineticist to be undesirable as subjects for other reasons.